{
  "id": 17891016,
  "title": "Samsung Biologics Wins 434.3 Billion Won Biopharma Order",
  "url": "https://urgent.news/2026/11/03/samsung-biologics-wins-434-3-billion-won-biopharma-order",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-11-03T02:04:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=280291"
  },
  "original_language": "en",
  "account": "Samsung Biologics has secured a major biopharma contract, worth 434.3 billion won ($324.80 million), with a global pharmaceutical company. This contract, a long-term commitment until December 31, 2031, is expected to provide the company with a stable order backlog. The specific client and product names remain undisclosed due to contractual confidentiality. This brings Samsung Biologics' cumulative order value since its establishment to $22.3 billion. The company has signed nine contracts this year alone, further solidifying its position in the global bio market, according to market assessments. Samsung Biologics partners with many of the world's top 20 pharmaceutical companies, and its enduring relationships with these global entities likely contributed to the size of this contract. The company has been actively responding to the growing global demand for biopharmaceuticals and is expanding its diversified supply chains. The new contract is seen as a sign of Samsung Biologics' strengthened management stability, providing secured production volumes for the early 2030s.",
  "summary": "Samsung Biologics is strengthening its mid- to long-term growth drivers by continuing to win large-scale orders in the global pharmaceutical market.Samsung Biologics disclosed on Nov. 3 that it signed a new contract manufacturing organization (CMO) agreement for biopharmaceuticals with a global phar",
  "key_points": [
    "Samsung Biologics secures $324.8M biopharma contract with global pharma company",
    "Contract valid until December 31, 2031, ensuring stable order backlog",
    "Company's cumulative order value reaches $22.3B since establishment"
  ],
  "editors_take": "Securing this long-term contract through 2031 reinforces the company's management stability by providing guaranteed production volumes and a predictable backlog to meet rising global biopharmaceutical demand.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}